ClinicalTrials.gg

Program

VV913

A development code. Also written as “VV913 4mg group”, “VV913 8mg group” and “VV913 15mg group”.

Its studies are mostly in Premature Ejaculation, led by Vigonvita Life Sciences.

Furthest: phase 2, since Jul 19, 20264 company-led studies, 4 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vigonvita Life Sciences44 open or runningphase 2since Jul 19, 2026Jan 19, 2026Dec 31, 2026phase 1 · NCT07565792

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 19, 2026First study: phase 1 study in Healthy VolunteersFirst studyNCT07372703 · 56 planned · China
  2. Mar 27, 2026Early phase 1 study in Healthy VolunteersNCT07507838 · 24 planned · China
  3. Apr 27, 2026Phase 1 study in Healthy VolunteersNCT07565792 · 12 planned · China
  4. Jul 19, 2026Phase 2 study in Premature EjaculationPhase 2 reachedNCT07722780 · 500 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Healthy VolunteersNCT07565792
  2. Dec 31, 2026Primary completion: early phase 1 study in Healthy VolunteersNCT07507838
  3. Dec 31, 2027Primary completion: phase 2 study in Premature EjaculationNCT07722780

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07722780Premature Ejaculation · China2Not yet recruitingDec 31, 2027500
NCT07565792Healthy Volunteers · China1RecruitingDec 31, 202612
NCT07507838Healthy Volunteers · ChinaEarly 1RecruitingDec 31, 202624
NCT07372703Healthy Volunteers · China1RecruitingSep 202656

How it is read

Names in the registry

  • “VV913”, 3 entries
  • “VV913 4mg group”, 2 entries
  • “VV913 8mg group”, 2 entries
  • “VV913 15mg group”, 2 entries
  • “VV913 2mg Capsules”, 1 entry

Codes read as this program: VV913.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.